Book a Meeting
Creative Biolabs - ADCC+ Antibody

Anti-Siglec-8 Antibody, ADCC Enchanced (BioBet-CB-084LX) (CAT#: BioBet-CB-084LX) Datasheet

Target
Siglec-8
Isotype
IgG1
Description
Anti-Siglec-8 Antibody, ADCC Enchanced (BioBet-CB-084LX) is a glycosylation-modified anti-Siglec-8 therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Siglec-8 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Siglec-8
Full Name
Sialic acid binding Ig like lectin 8
Background
Sialic acid-binding immunoglobulin (Ig)-like lectins, or SIGLECs (e.g., CD33 (MIM 159590)), are a family of type 1 transmembrane proteins each having a unique expression pattern, mostly in hemopoietic cells. SIGLEC8 is a member of the CD33-like subgroup of SIGLECs, which are localized to 19q13.3-q13.4 and have 2 conserved cytoplasmic tyrosine-based motifs: an immunoreceptor tyrosine-based inhibitory motif, or ITIM (see MIM 604964), and a motif homologous to one identified in signaling lymphocyte activation molecule (SLAM; MIM 603492) that mediates an association with SLAM-associated protein (SAP; MIM 300490) (summarized by Foussias et al., 2000 [PubMed 11095983]).[supplied by OMIM, May 2010]
Alternative Names
SIGLEC8; sialic acid binding Ig like lectin 8
Gene ID
27181
UniProt ID
Q9NYZ4
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-CB-084LX
Host
Humanized
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human Siglec-8 (Lirentelimab) Antibody is derived from clone Lirentelimab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the Siglec-8, and it is intended for the research of Eosinophilic gastritis.
Antibody Indication
Eosinophilic gastritis

Eosinophilic gastritis

Related Products

Anti-Siglec-8 Antibody, Non-Fucosylated (HEKA) (CAT#: BioBet-1673ZP)
Anti-Siglec-8 Antibody, Non-Fucosylated (2E2) (CAT#: BioBet-1671ZP)
Anti-Siglec-8 Antibody, Non-Fucosylated (2C4) (CAT#: BioBet-1672ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *

ISO 9001 Certified - Creative Biolabs Quality Management System.
© 2025 Creative Biolabs. All rights reserved.
Merry Christmas Merry Christmas